Fundamental Analysis of Metabolic Explorer(EPA:METEX) stock

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to METEX. METEX was compared to 65 industry peers in the Chemicals industry. METEX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, METEX is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

METEX had negative earnings in the past year.

METEX had a negative operating cash flow in the past year.

In the past 5 years METEX reported 4 times negative net income.

In the past 5 years METEX reported 4 times negative operating cash flow.

1.2 Ratios

The Return On Assets of METEX (-19.08%) is worse than 89.06% of its industry peers.

With a Return On Equity value of -51.84%, METEX is not doing good in the industry: 89.06% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-19.08%
ROE	-51.84%
ROIC	N/A

ROA(3y)-0.39%

ROA(5y)-4.87%

ROE(3y)-8.69%

ROE(5y)-13.58%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

METEX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

METEX does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for METEX remains at a similar level compared to 1 year ago.

The number of shares outstanding for METEX has been increased compared to 5 years ago.

Compared to 1 year ago, METEX has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of 0.19, we must say that METEX is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of 0.19, METEX is not doing good in the industry: 90.63% of the companies in the same industry are doing better.

METEX has a Debt/Equity ratio of 0.92. This is a neutral value indicating METEX is somewhat dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.92, METEX is doing worse than 79.69% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.92
Debt/FCF	N/A
Altman-Z	0.19

ROIC/WACCN/A

WACC5.97%

2.3 Liquidity

METEX has a Current Ratio of 2.19. This indicates that METEX is financially healthy and has no problem in meeting its short term obligations.

METEX has a Current ratio of 2.19. This is in the better half of the industry: METEX outperforms 64.06% of its industry peers.

METEX has a Quick Ratio of 1.31. This is a normal value and indicates that METEX is financially healthy and should not expect problems in meeting its short term obligations.

METEX has a Quick ratio (1.31) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.19
Quick Ratio	1.31

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

METEX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -137.50%.

The Revenue for METEX has decreased by -36.59% in the past year. This is quite bad

The Revenue has been growing by 123.77% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-137.5%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%32.65%

Revenue 1Y (TTM)-36.59%

Revenue growth 3Y765.1%

Revenue growth 5Y123.77%

Sales Q2Q%-46.56%

3.2 Future

The Earnings Per Share is expected to grow by 23.69% on average over the next years. This is a very strong growth

The Revenue is expected to grow by 2.34% on average over the next years.

EPS Next Y1.9%

EPS Next 2Y23.83%

EPS Next 3Y23.69%

EPS Next 5YN/A

Revenue Next Year-44.08%

Revenue Next 2Y-9.58%

Revenue Next 3Y2.34%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for METEX. In the last year negative earnings were reported.

Also next year METEX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

METEX's earnings are expected to grow with 23.69% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y23.83%

EPS Next 3Y23.69%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

METEX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

Metabolic Explorer

EPA:METEX (5/6/2024, 7:00:00 PM)

0.1214

+0 (+1.17%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap6.16M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-19.08%
ROE	-51.84%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.64

Health

		Industry Rank	Sector Rank
Debt/Equity	0.92
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.19
Quick Ratio	1.31
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-137.5%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y1.9%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-36.59%

Revenue growth 3Y765.1%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

Metabolic Explorer (METEX.PA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens